ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

OMG!  Tuesday 17 August: Summary of last week’s newsletter

Share On Facebook
share on Linkedin
Print

The OMG newsletter recommends at least 15 companies each month, using the writers’ experience of small caps to give you a winning edge. Last week they wrote about Chaarat Gold Holdings and Byotrol. Read about these Opportunities 4 Material Gains!

©

 

Mid-week Tip Wednesday 11th August

Chaarat Gold Holdings (LSE: CGH) who operate a gold mine in Kapan Armenia with assets at various stages of development in the Kyrgyz Republic. The recent Trading update seemed to have stimulated Directors into buying £560,000 worth of shares at 22p. The 4.6% production reduction at the mine in Kapan to 25,896 oz gold equivalent was mitigated by slight reduced in the  cost of production at $1,063 oz. There was also a significant increased on third-party ore production to 70kt against zero.  The realised gold price for the quarter was 7% higher at $1,783. This gives a strong financial performance with preliminary unaudited EBITDA contribution of $13.5m which is up 229%  for the first half to announced in September. Earlier this year a $52m funding with shares and a £20m Loan conversion was concluded at 26p. The delayed mine debt finance could soon be in place. Speculative Buy.

 

Results Preview 16th August

Byotrol (LSE: BYOT) is a specialist infection prevention and control company. It provides low toxicity and non-alcohol-based products with a broad-based and targeted efficacy across all microbial classes; bacteria, viruses (including coronavirus), fungi, moulds, mycobacteria and algae.  Its reporting finals to March 2021 this  Thursday and Aprils Trading update expect sales to be substantially ahead and could nearly double. The shares on Covid assisted ‘punter/ investing’ have been up to 10pyotrol is on course to report a leap from last year’s PBT of £0.33m on revenues of £6m to £1.5m PBT on £11m this would give a P/E of 19x.  Based on modest revenue growth as the Covid sales surge recedes next year’s earning (2021-22) are expected to be improved economies of scale and EPS to grow by 23% to 0.39p a giving a prospective P/E of 15x.Still attractive when it returns to a new normal growth, but short-term share price volatility may give some lower priced  buying opportunities.

 

Reviews from 16th  July 

Advanced Oncotherapy (LSE: AVO)

Empresaria (LSE: EMR

Immupharma (LSE IMM)

Northbridge Industrial Services (LSE: NBI).

Lok’nStore (LSE: LOK)

Checkit (LSE: CKT)

Minds + Machines (LSE: MMX)

Eleco (LSE: ELCO)

 

Finally  Enjoy the summer break

 

OMG!  Opportunity for Massive Gains is a Premium Newsletter on ADVFN with two reports each week written by experienced small cap specialists. To get trips like this every week, sign up here.

 

CLICK HERE TO REGISTER FOR FREE ON ADVFN, the world's leading stocks and shares information website, provides the private investor with all the latest high-tech trading tools and includes live price data streaming, stock quotes and the option to access 'Level 2' data on all of the world's key exchanges (LSE, NYSE, NASDAQ, Euronext etc).

This area of the ADVFN.com site is for independent financial commentary. These blogs are provided by independent authors via a common carrier platform and do not represent the opinions of ADVFN Plc. ADVFN Plc does not monitor, approve, endorse or exert editorial control over these articles and does not therefore accept responsibility for or make any warranties in connection with or recommend that you or any third party rely on such information. The information available at ADVFN.com is for your general information and use and is not intended to address your particular requirements. In particular, the information does not constitute any form of advice or recommendation by ADVFN.COM and is not intended to be relied upon by users in making (or refraining from making) any investment decisions. Authors may or may not have positions in stocks that they are discussing but it should be considered very likely that their opinions are aligned with their trading and that they hold positions in companies, forex, commodities and other instruments they discuss.

Leave A Reply

 
Do you want to write for our Newspaper? Get in touch: newspaper@advfn.com